Kliniske studier vedrørende akut og kronisk tromboembolisk sygdom
A Study of Flexible Dosage in Extended PE/DVT Treatment
EINSTEIN CHOICE:
A Study of Xarelto® with a Flexible Choice of Dosage for Extended Treatment of Recurrent VTE
Objective
- To compare the efficacy and safety profile of 20 mg OD or 10 mg OD Xarelto doses with aspirin for extended treatment of recurrent VTE, in patients who had been treated for 6–12 months with an anticoagulant therapy1
Study Design

* ≤7 days of treatment interruption prior to randomisation. † Patients randomised after the requisite number of primary efficacy outcomes was reached were treated for ≥6 months.
Patients’ Clinical Characteristics

Key Findings
- Efficacy
- Both 10 mg OD and 20 mg OD Xarelto doses significantly reduced the risk of recurrent VTE vs aspirin‡,1
- Safety
DVT, deep vein thrombosis; OD, once daily; PE, pulmonary embolism; VTE, venous thromboembolism.
‡ For VTE extended treatment.
PP-XAR-ALL-1816-1
Referencer
- Weitz JI, et al. N Engl J Med. 2017;376:1211–1222. Weitz JI, et al. N Engl J Med. 2017;376:1211–1222. Return to content